April 12, 2011Open Access

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Key Points

Key points are not available for this paper at this time.

Abstract

Among outpatients with RA in whom adalimumab was started over 3 years, the development of antidrug antibodies was associated with lower adalimumab concentration and lower likelihood of minimal disease activity or clinical remission.

AIに質問

Bookmark

View Full Paper

Cite This Study

G. M. Bartelds (Tue,) studied this question.

synapsesocial.com/papers/69d76666b1cb92dd1bb8ae6e https://doi.org/https://doi.org/10.1001/jama.2011.406

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study2009 · 223 citations
2Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis1995 · 6,235 citations
3Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease2003 · 101 citations
4Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study2008 · 135 citations
5Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice2010 · 37 citations

AIに質問

Bookmark

View Full Paper